BNET Industries
Market Cap:$147.9B
Last Fiscal Year Sales:$48.4B
- Public
- US
Dow Jones Description
Taking care of you and your four-legged friends too! Pfizer Inc. (NYSE: PFE), based in New York, NY, discovers, develops, manufactures and sells prescription medications for humans and animals. Employing about 115,000 people, this $51.3 billion company operates in three segments: Human Health, Consumer Healthcare and Animal Health. Together, these segments cover treatments for diseases such as cardiovascular and metabolic diseases, medications for oral care, tobacco dependence, and products for prevention and treatment of diseases in livestock and pets.
Number of Employees 81,800
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
Recent Events
-
Pfizer joins partnership with Calif. firm: Collaboration planned with Crown Bioscience for cancer research
-
Research and Markets: The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to...
-
Science and Technology: Pfizer to buy Croatian drug patent
-
Bristol-Myers Squibb Raises Exchange Offer Price For Mead Johnson Shares - Update
-
'IT boosts efficiency & innovation'
-
Inspector General Saved Billions in Healthcare This Year
-
Pfizer and B.C. launch $9M collaboration to tackle cancer
-
Reportlinker Adds Growth Factors Blood And Tissue - A World Report
-
Pfizer receives EC nod for Prevenar 13
-
Protalix Completes NDA Submission for taliglucerase alfa for the Treatment of Gaucher's Disease
-
Pfizer Inc. PFE JOBS Acquires Rights to Protalix Biotherapeutics's Gaucher Drug in Deal Worth $115M
-
Conservationists salute two corporations
-
Pfizer PFE Will Not Renew Ethical Distribution Agreement Term with MWI Veterinary Supply MWIV
-
2009: The Year That Was For Pfizer
-
A 2nd Loss for Pfizer in Drug Suits
-
Pfizer acquires stem cell therapies assets of Axordia
-
Standpoint Raised Its FY10 Price Target on Pfizer PFE to $24
-
ImmunoVaccine signs exclusive licence deal with Pfizer
-
Pfizer Animal Health selects Bader Rutter as agency of record
News & Analysis
Filter by
chinabio today and pfizer inc. - All News and Analysis
Pfizer Forms Cancer Collaboration with Crown Bioscience
Seeking Alpha
- 2009-12-10
ChinaBio Today submits: Crown Bioscience, a pre-clinical CRO providing biology services for oncology indications, will collaborate with Pfizer (NYSE: PFE) to research and develop novel drugs for cancers that are prevalent in Asia and remain unaddressed medical needs. Crown will receive an upfront payment and research funding, as well...
Pfizer Increases R&D Commitment in China
Seeking Alpha
- 2009-11-26
ChinaBio Today submits: Pfizer (NYSE: PFE) will expand its China R&D operations by adding facilities in central and western China, according to a Reuters story. The company will build a new clinical R&D center in Wuhan, which will support global clinical drug programs, including Phase I-IV clinical trials. Pfizer...
Pfizer Is Best Positioned Big Pharma in China - Goldman
Seeking Alpha
- 2009-11-20
ChinaBio Today submits: In an investment review of Pfizer (NYSE: PFE), Goldman Sachs said sales in emerging growth markets would become a significant factor in the company’s revenues, a fact that it considers underappreciated by stock market investors. China is the major emerging market for Pfizer. Goldman expects...
BMP Sunstone Partners with Pfizer to Distribute Endometriosis Treatment in China
Seeking Alpha
- 2009-11-11
ChinaBio Today submits: BMP Sunstone Corporation (NSDQ: BJGP) and Pfizer China (NYSE: PFE) have formed a strategic partnership to distribute and promote Depo-Provera (Medroxy-progesterone Acetate), a Pfizer product used to treat endometriosis, in China. Endometriosis is a medical condition in women of childbearing age that can cause significant pain....
Pfizer's Cutbacks Reflect Difficulties Facing Big Pharma
Seeking Alpha
- 2009-11-10
ChinaBio Today submits: Pfizer (NYSE: PFE) announced it would close six out of its 20 R&D facilities around the globe as part of its post-Wyeth-acquisition consolidation. Some employees will be transferred to other facilities, while others will be let go. Pfizer did not disclose how many of its R&D...
China Requires One Divestiture for Pfizer / Wyeth Merger
Seeking Alpha
- 2009-10-01
ChinaBio Today submits: The Anti-Monopoly Bureau of China’s Ministry of Commerce (MOFCOM) has given its okay to the merger between Pfizer (NYSE: PFE) and Wyeth (NYSE: WYE). However, MOFCOM will require that Pfizer divest its swine mycoplasmal pneumonia vaccine business. Pfizer has been negotiating with the Anti-Monopoly Bureau on...
Pfizer, Fudan University Partner to Offer New Graduate Program in China
Seeking Alpha
- 2009-07-31
ChinaBio Today submits: Pfizer (NYSE: PFE) and Fudan University, located in Shanghai, are working together to create a graduate program in Clinical Data Management and Statistical Programming. Starting in September, the University will offer a three-year Masters Degree program, the first such program in China. The program will combine...
Pfizer Underwrites Basic Research at Shanghai Institutes
Seeking Alpha
- 2009-07-30
ChinaBio Today submits: Pfizer (NYSE: PFE) has teamed up with the Shanghai Institutes for Biological Sciences (SIBS) to do basic research. The biggest of pharmas will underwrite $500,000 of health-related basic research projects at SIBS for each of the next three years. Pfizer and SIBS will select the research...
Pfizer: Looking to Do Deals in Emerging Markets
Seeking Alpha
- 2009-06-21
ChinaBio Today submits: Pfizer Inc (NYSE: PFE) will use acquisitions and partnerships in an effort to become the number one drug seller in emerging markets such as China. Currently, Pfizer occupies the number three position. The emerging markets sector is worth $80 billion currently, and is expected to grow...
Pfizer Takes Steps to Provide Healthcare for China's Poor
Seeking Alpha
- 2009-03-24
ChinaBio Today submits: Pfizer (NYSE: PFE) has teamed up with non-profit PlaNet Finance to conduct in-depth research on the healthcare needs of the working poor in China. The study will examine the availability and existing sources of medicines, patient purchasing patterns, and the level of access to medical services....
- 1
- 2
Industry Transcripts by Seeking Alpha
-
Peregrine Pharmaceuticals Inc. F2Q10 (Qtr End 31/10/09) Earnings Call Transcript
on Dec 10, 2009about PPHM
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone 3 votes
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity" 3 votes
- Why J&J's Stelara Launch Should Target Dermatologists First 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
Presented by American Express